Clinical Trial Detail

NCT ID NCT04487080
Title A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)
Recruitment Not yet recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

lung non-small cell carcinoma

Therapies

JNJ-61186372 + Lazertinib

Lazertinib

Osimertinib

Age Groups: adult senior

No variant requirements are available.